A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma

Clinical Cancer Research

Volumn 10, Issue 1 I, 2004, Pages 4-12

  Riley, Richard D ^a   Heney, David ^a   Jones, David R ^a   Sutton, Alex J ^a   Lambert, Paul C ^a   Abrams, Keith R ^a   Young, Bridget ^b   Wailoo, Alan J ^c   Burchill, Susan A ^d  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FERRITIN; HERMES ANTIGEN; HOMOVANILLIC ACID; LACTATE DEHYDROGENASE; NERVE GROWTH FACTOR RECEPTOR; NEURON SPECIFIC ENOLASE; TUMOR MARKER; VANILMANDELIC ACID;

CANCER RESEARCH; CANCER SCREENING; CHROMOSOME 1P; DATA ANALYSIS; DIAGNOSTIC VALUE; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL LITERATURE; METHODOLOGY; MULTIDRUG RESISTANCE; NEUROBLASTOMA; PARAMETER; PATIENT INFORMATION; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; REVIEW; SAMPLE SIZE; STANDARDIZATION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TECHNIQUE;

GENETIC MARKERS; HUMANS; NEOPLASM PROTEINS; NEUROBLASTOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 1642453771     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1051-2     Document Type: Review

References (33)

1. Brodeur, G. M., and Castleberry, R. P. Neuroblastoma. In: P.A. Pizzo and D. G. Poplack (eds.), Principles and Practice of Paediatric Oncology, pp. 761-797. Philadelphia: J. B. Lippincott Co., 1997.
2. Maris, M., and Matthay, K. K. Molecular biology of neuroblastoma. J. Clin. Oncol., 17: 2264-2279, 1999.
3. Grovas, A., Fremgen, A., Rauck, A., Ruymann, F. B., Hutchinson, C. L., Winchester, D. P., and Menck, H. R. The National Cancer Data Base Report on patterns of childhood cancer in the United States. Cancer (Phila.), 80: 2321-2332, 1997.
4. Cotterill, S. J., Pearson, A. D., Pritchard, J., Foot, A. B., Roald, B., Kohler, J. A., and Imeson, J. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur. J. Cancer, 36: 901-908, 2000.
5. NHS Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness: CRD Guidelines for Those Carrying Out or Commissioning Reviews. CRD Report 4. University of York: NHS Centre for Reviews and Dissemination, 1996.
6. Riley, R. D., Burchill, S. A., Abrams, K. R., Heney, D., Sutton, A. J., Jones, D. R., Lambert, P. C., Young, B., Wailoo, A. J., and Lewis, I. J. A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur. J. Cancer, 39: 19-30, 2003.
7. Riley, R. D., Burchill, S. A., Abrams, K. R., Heney, D., Lambert, P. C., Jones, D. R., Sutton, A. J., Young, B., Wailoo, A. J., and Lewis, I. J. A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. Health Technol. Assess., 7: 1-162, 2003.
8. Brodeur, G. M. Molecular basis for heterogeneity in human neuroblastomas. Eur. J. Cancer, 31: 505-510, 1995.
9. Sutton, A. J., Abrams, K. R., Jones, D. R., Sheldon, T. A., and Song F. (eds.). Methods for Meta-analysis in Medical Research. London: John Wiley, 2000.
10. Parmar, M. K. B., Torri, V., and Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med., 17: 2815-2834, 1998.
11. Altman, D. G. Systematic reviews of studies of prognostic variables. In: M. Egger, G. Davey Smith, D. G. Altman (eds.), Systematic Reviews in Health Care: Meta-Analysis in Context, Chapter 13, 228-247. London: BMJ Publishing Group; 2001.
12. Begg, C. B., and Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics, 50: 1088-101, 1994.
13. Egger, M., Smith, G. D., Schneider, M., and Minder, C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J., 315: 629-634, 1997.
14. Duval, S., and Tweedie, R. A non-parametric "trim and fill" method of assessing publication bias in meta-analysis. Biometrics, 56: 455-463, 2000.
15. Riley, R. D., Abrams, K. R., Sutton, A. J., Lambert, P. C., Jones, D. R., Heney, D., and Burchill, S. A. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br. J. Cancer, in press.
16. Sawada, T., Todo, S., Fujita, K., Iino, S., Imashuku, S., and Kusunok, T. Mass screening of neuroblastoma in infancy. Am. J. Dis. Child., 136: 710-712, 1982.
17. Scriver, C. R., Gregory, D., Bernstein, M., Clow, C. L., Weisdorf, T., Dougherty, G. E., Auray-Blais, C., Giguere, R., Lemieux, B., and Laberge, C. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec. CMAJ, 136: 952-956, 1987.
18. Egger, M., Davey Smith, G., and Altman, D. G. (eds.). Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Publishing Group, 2001.
19. Egger, M., Davey Smith, G., O'Rourke, K. Rational, potentials and promise of systematic reviews. In: M. Egger, G. Davey Smith, D. G. Altman (eds.), Systematic Reviews in Health Care: Meta-Analysis in Context, pp. 3-19. London: BMJ Publishing Group, 2001.
20. Egger, M., Zellweger-Zähner, T., Schneider, M., Junker, C., Lengeler, C., and Antes, G. Language bias in randomised controlled trials published in English and German. Lancet, 350: 326-329, 1997.
21. Brodeur, G. M., Look, A. T., Shimada, H., Hamilton, V. M., Maris, J. M., Hann, H. W., Leclerc, J. M., Bernstein, M., Brisson, L. C., Brossard, J., Lemieux, B., Tuchman, M., and Woods, W. G. Biological aspects of neuroblastomas identified by mass screening in Quebec. Med. Pediatr. Oncol., 36: 157-159, 2001.
22. Abel, F., Ejeskar, K., Kogner, P., and Martinsson, T. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24. Br. J. Cancer, 81: 1402-1409, 1999.
23. Bown, N., Cotterill, S., Lastowska, M., O'Neill, S., Pearson, A. D., Plantaz, D., Meddeb, M., Danglot, G., Brinkschmidt, C., Christiansen, H., Laureys, G., and Speleman, F. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med., 340: 1954-1961, 1999.
24. Cunsolo, C. L, Bicocchi, M. P., Petti, A. R., and Tonini, G. P. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status. Br. J. Cancer, 83: 1295-1300, 2000.
25. Lastowska, M. Cotterill, S., Pearson, A. D., Roberts, P., McGuckin, A., Lewis, I., and Bown, N. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U. K. Children's Cancer Study Group and the U. K. Cancer Cytogenetics Group. Eur. J. Cancer, 33: 1627-1633, 1997.
26. Plantaz, D., Mohapatra, G., Matthay, K. K., Pellarin, M., Seeger, R. C., and Feuerstein, B. G. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am. J. Pathol., 150: 81-89, 1997.
27. Vandesompele, J. Speleman, F., Van Roy, N., Laureys, G., Brinskchmidt, C., Christiansen, H., Lampert, F., Lastowska, M., Bown, N., Pearson, A., Nicholson, J. C., Ross, F., Combaret, V., Delattre, O., Feuerstein, B. G., and Plantaz, D. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? Med. Pediatr. Oncol., 36: 5-10, 2001.
28. Bown, N., Lastowska, M., Cotterill, S., O'Neill, S., Ellershaw, C., Roberts, P., Lewis, I., and Pearson, A. D. 17q gain in neuroblastoma predicts adverse clinical outcome. Med. Pediatr. Oncol., 36(1): 14-19, 2001.
29. Altman, D. G., and Lyman, G. H. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res. Treat., 52: 289-303, 1998.
30. Hutchon, D. J. R. Publishing raw data and real time statistical analysis on e-journals. Br. Med. J., 322: 530, 2001.
31. Sakamoto, J. Teramukai, S., Koike, A., Saji, S., Ohashi, Y., and Nakazato, H. Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. Cancer (Phila.), 77: 2206-2212, 1996.
32. Look, M. P., van Putten, W. L., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., Sweep, C.G., Ulm, K., Peyrat, J. P., Martin, P. M., Magdelenat, H., Brunner, N., Duggan, C., Lisboa, B. W., Bendahl, P. O., Quillien, V., Daver, A., Ricolleau, G., Meijer-van Gelder, M. E., Manders, P., Fiets, W. E., Blankenstein, M.A., Broet, P., Romain, S., Daxenbichler, G., Windbichler, G., Cufer, T., Borstnar, S., Kueng, W., Beex, L. V., Klijn, J. G., O'Higgins, N., Eppenberger, U., Janicke, F., Schmitt, M., and Foekens, J. A. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI- 1 in 8377 breast cancer patients. J. Natl. Cancer Inst., 94: 116-128, 2002.
33. Park, K. C. Schwimmer, J., Shepherd, J. E., Phelps, M. E., Czernin, J. R., Schiepers, C., and Gambhir, S. S. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann. Surg., 233: 310-319, 2001.